Sale!

CACNA1S Gene Malignant Hyperthermia Type 5 Genetic Test

Original price was: $700.Current price is: $500.

-29%

The CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test is a cutting-edge diagnostic tool that identifies mutations in the CACNA1S gene responsible for malignant hyperthermia susceptibility type 5. This comprehensive genetic analysis utilizes Next-Generation Sequencing (NGS) technology to detect specific genetic variants that can trigger life-threatening reactions to certain anesthetics and muscle relaxants. The test provides crucial information for individuals with family history of malignant hyperthermia, unexplained muscle rigidity, or those planning surgical procedures. Results help guide anesthesia choices and prevent potentially fatal complications during medical procedures. Available for only $500 USD, this test offers peace of mind and proactive healthcare management for at-risk individuals and families.

Trusted Testing. Expert Care. Guaranteed Privacy.

  • Accredited and Trusted
  • Expert Scientists, Advanced Technology
  • Data Privacy Guaranteed
Guaranteed Safe Checkout

CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test

Comprehensive Genetic Testing for Malignant Hyperthermia Susceptibility

The CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test represents a breakthrough in genetic diagnostics for individuals at risk of malignant hyperthermia, a rare but potentially fatal condition triggered by certain anesthetic agents. This advanced testing method provides crucial insights into genetic susceptibility, enabling proactive medical management and personalized treatment planning.

What This Test Measures and Detects

This specialized genetic test utilizes Next-Generation Sequencing (NGS) technology to analyze the CACNA1S gene, specifically targeting mutations associated with malignant hyperthermia susceptibility type 5. The test identifies:

  • Pathogenic variants in the CACNA1S gene that increase susceptibility to malignant hyperthermia
  • Specific genetic mutations affecting calcium channel function in skeletal muscle
  • Inherited genetic patterns that may predispose family members to this condition
  • Genetic markers that help predict anesthetic sensitivity and risk assessment

Who Should Consider This Test

This genetic test is particularly recommended for individuals experiencing:

  • Family history of malignant hyperthermia or unexplained anesthetic complications
  • Unexplained muscle rigidity or spasms during or after anesthesia
  • Planned surgical procedures requiring general anesthesia
  • Relatives of individuals diagnosed with malignant hyperthermia susceptibility
  • Unexplained episodes of high fever, muscle breakdown, or metabolic acidosis during medical procedures
  • Professional athletes or individuals with muscle-related symptoms seeking comprehensive genetic evaluation

Key Benefits of Genetic Testing

Undergoing the CACNA1S Gene Malignant Hyperthermia Type 5 test offers numerous advantages:

  • Early Risk Identification: Detect genetic susceptibility before exposure to triggering agents
  • Personalized Anesthesia Planning: Enable healthcare providers to select safe anesthetic protocols
  • Family Screening: Identify at-risk relatives who may benefit from testing
  • Preventive Healthcare: Implement proactive measures to avoid life-threatening complications
  • Peace of Mind: Reduce anxiety about potential anesthetic reactions during medical procedures
  • Comprehensive Genetic Counseling: Receive expert guidance on test results and implications

Understanding Your Test Results

Your genetic test results will be carefully interpreted by our team of genetic specialists and neurologists. Results typically fall into three categories:

  • Positive Result: Indicates the presence of a pathogenic variant in the CACNA1S gene, confirming susceptibility to malignant hyperthermia type 5. This information allows for proper medical alert documentation and safe anesthesia planning.
  • Negative Result: Suggests no detected mutations in the analyzed regions of the CACNA1S gene, though genetic counseling is still recommended for comprehensive risk assessment.
  • Variant of Uncertain Significance: Some genetic changes may require additional family studies or research to determine clinical significance.

All results include detailed interpretation and recommendations for next steps, including genetic counseling and family testing considerations.

Test Pricing Information

Test Name Discount Price Regular Price
CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test $500 USD $700 USD

Nationwide Testing Availability

We have conveniently located testing centers across the United States, including major metropolitan areas such as New York, Los Angeles, Chicago, Houston, Phoenix, Philadelphia, San Antonio, San Diego, Dallas, and San Jose. Our state-of-the-art facilities ensure accurate sample collection and rapid processing.

Pre-Test Requirements

Before scheduling your test, please ensure you have:

  • Complete clinical history documentation
  • Scheduled genetic counseling session to create a detailed family pedigree chart
  • Understanding of test implications and potential outcomes
  • Proper identification and insurance information if applicable

Take Control of Your Genetic Health Today

Don’t leave your anesthetic safety to chance. The CACNA1S Gene Malignant Hyperthermia Type 5 NGS Genetic DNA Test provides critical information that could save your life during medical procedures. Our team of genetic specialists and neurologists is ready to guide you through the testing process and help you understand your results.

Call or WhatsApp us today at +1(267) 388-9828 to schedule your genetic test consultation and take the first step toward personalized medical safety planning.

With a turnaround time of 3-4 weeks and multiple sample collection options including blood, extracted DNA, or blood spot on FTA card, getting tested has never been more convenient. Protect yourself and your family with comprehensive genetic testing from General Genetics Corporation.